alexa F-CALPROTECTIN HELPS REDUCING COSTS AND RISKS FOR PATIENTS IN THE DIAGNOSIS OF COLONIC PATHOLOGY: A PROSPECTIVE REAL-LIFE STUDY FROM THE CLINICAL HOSPITAL OF ZARAGOZA
ISSN: 2167-1079

Primary Healthcare: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd World Congress on Health Economics Policy & Outcomes Research
June 29-30, 2017|Madrid, Spain

Barbara Mascialino, Alberto Lue, Juan Jose Puente, Erika Alfambra, Maria Teresa Arroyo, Carmen Andalucia and Fernando Gomollon
Hospital Clinico Universitario Lozano Blesa, Spain.
Thermo Fisher Scientific, Sweden
ScientificTracks Abstracts: Prim Health Care
DOI: 10.4172/2167-1079-C1-008
Abstract
Colonoscopy represents the gold standard in case of suspected colonic pathology. However, availability is limited and it brings about avoidable risks for the patients and important costs. F-Calprotectin is a fecal marker of intestine inflammation capable to differentiate between organic and functional intestinal disorder and could therefore potentially, be used as a pre-endoscopic tool to identify patients that could potentially avoid a colonoscopy. The purpose of this observational prospective study was to quantify in a Secondary Care (SC) setting in Zaragoza (Spain) the burden of colonoscopy in 87 consecutive unselected patients referred to colonoscopy either by Primary Care (PC) or SC doctors (gastroenterologists, or other specialists), and to evaluate the economic impact associated with the pre-endoscopic usage of F-Calprotectin. Methodology: Diagnosis was established by colonoscopic investigation, and F-Calprotectin levels were evaluated by means of EliA Calprotectin 2 at both the recommended 50 mcg/g, and at the optimal 234.5 mcg/g cut-offs (sensitivity=69%, specificity=87%). Real-life data (including diagnosis, costs, colonoscopy-related complications, and resource utilization) were prospectively collected. Three scenarios (S) were compared: the actual situation (S1) and two simulations (S2=considering patients sent to colonoscopy by PC doctors only, S3=all patients) in which F-Calprotectin is used to select which patients require further investigations. Findings: In S1, 71 patients (81.6%) were declared healthy after colonoscopy. Using the optimal cut-off, the actual total cost for visits and procedures was 75875€ (average cost/patient 872€); 4.6% of the patients experienced colonoscopy-related complications, which accounted for 7.9% of the total costs. F-Calprotectin reduces the average cost/patient by 250€ (29%) in S2, and by 427€ (49.0%) in S3. The table summarizes the main economic and health effect results at both cut-offs. Conclusion: Results show that the usage of F-Calprotectin as pre-endoscopic diagnostic tool is associated with less colonoscopies, less complications, and important cost savings ascribable to reduced resource utilization.
Biography

Barbara Mascialino works as Health Economics and Outcome Research Manager at Thermo Fisher Scientific Immuno Diagnostics in Sweden. Barbara is a nuclear physicist with more than 15 years of experience in epidemiology, modelling and data analysis.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords